Valiant Laboratories Limited
Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals
Key metrics
Price as of 2026-04-29
Sign in for full ratios and TTM. Learn about these metrics →
Share price
NSE closing price from historical market data.
Loading price history…
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · NSE preferred when both exchanges report the same period · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 60 Cr | 41 Cr | 31 Cr | 19 Cr | 21 Cr | 35 Cr | 58 Cr | 47 Cr | 46 Cr | 52 Cr |
| Operating expenses (approx.) | -50,845 Cr | -51,270 Cr | -53,975 Cr | -58,721 Cr | -52,441 Cr | 33 Cr | 54 Cr | 44 Cr | 46 Cr | 53 Cr |
| EBITDA | 50,904 Cr | 51,310 Cr | 54,006 Cr | 58,740 Cr | 52,463 Cr | 2 Cr | 4 Cr | 2 Cr | 0.08 Cr | -0.26 Cr |
| OPM % | 85485.9% | 126644.1% | 176562.3% | 311053.5% | 244250.9% | 6.2% | 6.6% | 5.1% | 0.2% | -0.5% |
| Other income | 3 Cr | 2 Cr | 3 Cr | 3 Cr | 3 Cr | 2 Cr | -2 Cr | 0.66 Cr | 0.87 Cr | 0.63 Cr |
| Interest | 1,905 Cr | 1,869 Cr | 2,073 Cr | 5,287 Cr | 605 Cr | 0.06 Cr | 0.05 Cr | 0.07 Cr | 0.14 Cr | 0.68 Cr |
| Depreciation | 49,001 Cr | 49,448 Cr | 51,938 Cr | 53,456 Cr | 51,865 Cr | 0.52 Cr | 0.52 Cr | 0.53 Cr | 0.53 Cr | 2 Cr |
| Profit before tax | 1 Cr | -5 Cr | -3 Cr | -0.16 Cr | -4 Cr | 2 Cr | 0.94 Cr | 2 Cr | 0.28 Cr | -3 Cr |
| Tax % | 25.4% | 30.6% | 51.7% | -21438711.3% | -2130202.5% | -44.9% | 25.1% | 25.6% | 27.6% | -136.0% |
| Net profit | 79,341 Cr | -4 Cr | -1 Cr | -0.51 Cr | -5 Cr | 2 Cr | 0.70 Cr | 2 Cr | 0.20 Cr | -7 Cr |
| EPS (₹) | ₹0.24 | ₹-0.81 | ₹-0.33 | ₹-0.12 | ₹-1.09 | ₹0.54 | ₹0.16 | ₹0.42 | ₹0.04 | ₹-1.30 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|
| Sales | 182 Cr | 133 Cr | Sign in for TTM |
| Operating expenses (approx.) | -7,591 Cr | 138 Cr | Sign in for TTM |
| EBITDA | 7,774 Cr | -5 Cr | Sign in for TTM |
| OPM % | 4269.8% | -3.5% | Sign in for TTM |
| Other income | 10 Cr | 5 Cr | Sign in for TTM |
| Interest | 7,782 Cr | 0.18 Cr | Sign in for TTM |
| Depreciation | 2 Cr | 2 Cr | Sign in for TTM |
| Profit before tax | -0.77 Cr | -2 Cr | Sign in for TTM |
| Tax % | 141.5% | -45.5% | Sign in for TTM |
| Net profit | 31,963 Cr | -2 Cr | Sign in for TTM |
| EPS (₹) | ₹0.13 | ₹0.51 | Sign in for TTM |
| Dividend payout % | 0.0% | — | Sign in for TTM |
Trailing twelve months totals and margin rows
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2024 | Mar 2025 |
|---|---|---|
| Equity capital | 43 Cr | 43 Cr |
| Reserves | 193 Cr | 191 Cr |
| Borrowings | 76 Cr | 121 Cr |
| Other liabilities | 30 Cr | 45 Cr |
| Total liabilities | 343 Cr | 401 Cr |
| Fixed assets (net) | 50 Cr | 48 Cr |
| CWIP | 43 Cr | 156 Cr |
| Investments | 38 Cr | 0.0000 Cr |
| Other assets | 3,262 Cr | 193 Cr |
| Total assets | 343 Cr | 401 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2024 | Mar 2025 |
|---|---|---|
| Cash from operating activity | 2 Cr | 1 Cr |
| Cash from investing | -144 Cr | -53 Cr |
| Cash from financing | 152 Cr | 45 Cr |
| Net cash flow | 10 Cr | -7 Cr |
| Free cash flow (OCF − Capex) | -44 Cr | -113 Cr |
Ratios
Ratios as reported or derived per annual period.
| Metric | Mar 2024 | Mar 2025 |
|---|---|---|
| ROCE % | 2483.6% | -1.9% |
| ROE % | 13494.8% | -0.9% |
| Debtor days | 92 | 197 |
| Inventory days | 22 | 13 |
| Days payable | 56 | 132 |
| Cash conversion cycle | 57 | 78 |
| Debt / equity | 0.32 | 0.52 |
| Current ratio | 7.76 | 3.23 |
| Net debt / EBITDA | 0.0083 | — |
Compare with peers
Loading peers…